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CLINICAL AND ECONOMIC BENEFITS OF AN
INFECTIOUS DISEASE APPROVAL PROGRAM
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A one-month case-control comparison was completed to
evaluate infectious disease costs and outcomes utilizing
an antibiotic management service.
METHODS: Antibiotic approvals were obtained from the
Infectious Disease Pharmacy Specialist (case) or the Infec-
tious Disease fellows (control). Drug selection by the phar-
macy specialist was based on patient-specific and hospital-
specific parameters. Appropriateness of the drug therapy
approved by the service was also reviewed by the antibiotic
management physician. Charts were reviewed after antibi-
otic approval from case or control. They were also reas-
sessed when patients were discharged from the hospital.
Failure, reinfection, superinfection, and death were clinical
outcomes categorized. Cure rates were determined micro-
biologically and clinically. Cost analyses were based on
drug therapy, microbiology, length of treatment days, and
infectious disease consults. Antibiotics administered rea-
sonably without a documented infection were categorized
as "no infection." Patients were excluded if charts were
unattainable or outcome could not be determined.
RESULTS: A total of 255 patients receiving infectious
disease approval was reviewed. Of these, 130 patients
were controls and 125 were cases. Thirty-seven patients
were excluded. Cure rates for the Clinical Pharmacy Spe-
cialist versus the Infectious Disease fellows were 56%
versus 37%. Cost-effectiveness ratios per cure in 1993 US
dollars were $330 for the ID specialist versus $932 for
fellows considering drug costs. Cost-effectiveness ratios,
including total antibiotic management costs were $5,660
versus $11,252, respectively. When ratios were translated
to cost avoidance of the antibiotic management team,
savings were estimated at $94,416 for monthly drug costs
or $1,132,992/year. Total hospital costs savings during
infectious disease management interval were estimated to
be $576,876/month or $6,922,512/year.
CONCLUSIONS: The benefit of the antibiotic manage-
ment team improves cure rates while also decreasing cost
of treatment. This service pays for itself through its sav-
ings in drug and hospital costs while also improving pa-
tient outcomes.
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OBJECTIVE: A cost-avoidance model was developed to
determine potential cost savings (PCS) of a drug informa-
Abstracts
tion service (DIS) that results from answering a drug in-
formation request.
DESIGN: Patient-specific questions received by the drug
information service were reviewed and evaluated. A panel
determined whether or not appropriate drug therapy
would have been employed if the DIS had not been con-
sulted. Potential outcomes of drug information requests
were classified using a decision-tree model. A severity rat-
ing with potential cost avoidance was then attached to
each applicable request to predict PCS of the DIS.
RESULTS: Seventy-seven of the 570 drug information re-
sponses in the six-week study period had assessable PCS
to the institution. During the study interval, PCS were es-
timated to be $196,000. Projected to one year, PCS
reached $1.7 million. Of the savings noted, most were in
the categories of increased monitoring and additional
treatment. Annual PCS using a sensitivity analysis ranged
from $423,601 to $1,922,560 per year.
CONCLUSIONS: This model demonstrates that the DIS
at our institution does provide substantial cost avoidance.
This model may be modified to evaluate PCS in other ar-
eas of pharmacy practice.
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OBJECTIVE: To compare costs of hospitalisation for
lower respiratory tract infection (LRTI) in patients who
received antibiotics before admission versus those who
did not and in patients with and without underlying
chronic obstructive airways disease (COAD).
METHODS: All hospitalisations were analysed in a popu-
lation of 350,000 resident in Tayside during 1993-94.
Three groups of patients were identified by primary dis-
charge diagnosis in 1993-94 and previous admissions
from 1980 to 1992: (1) acute exacerbation of COAD, (2)
LRTI plus a secondary diagnosis of CO AD or previous ad-
mission with COAD, and (3) LRTI but no secondary
COAD or previous admission with COAD. Setting-specific
costs were applied (e.g., general medicine, intensive care,
geriatrics). Dispensed antibiotic prescribing in the 28 days
before admission was identified from all community phar-
macies. Non-parametric statistical tests were used.
RESULTS: Patients with COAD were more likely to have
received antibiotics before admission: COAD (n = 893)
49%; COAD+LRTI (n = 316) 43%; LRTI only (n =
822) 33%. Odds ratio for COAD vs LRTI only 1.90
(95% CI 1.56 to 2.31); COAD+LRTI vs LRTI only 1.50
(95% CI 1.15 to 1.96). Patients who received antibiotics
before admission had lower hospital costs than patients
who did not. Median total costs per admission: COAD
£1050 vs £1164 (p = 0.5); COAD+LRTI £1067 vs
£1354 (p = 0.5); LRTI only £1220 vs £1500; (p =
